



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/18446/2023

## European Medicines Agency decision P/0013/2023

of 31 January 2023

on the granting of a product specific waiver for efgartigimod alfa (Vyvgart), (EMA-002597-PIP09-22)  
in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Only the English text is authentic.**



# European Medicines Agency decision

P/0013/2023

of 31 January 2023

on the granting of a product specific waiver for efgartigimod alfa (Vyvgart), (EMA-002597-PIP09-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by argenx BV on 12 August 2022 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 December 2022 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

## **Article 1**

A waiver for efgartigimod alfa (Vyvgart), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

## **Article 2**

This decision is addressed to argenx BV, 7 Industriepark, 9052 – Zwijnaarde, Belgium.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/788533/2022

Amsterdam, 16 December 2022

## Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-002597-PIP09-22

### Scope of the application

**Active substance(s):**

Efgartigimod alfa

**Invented name and authorisation status:**

See Annex II

**Condition(s):**

Treatment of bullous pemphigoid

**Pharmaceutical form(s):**

Solution for injection

**Route(s) of administration:**

Subcutaneous use

**Name/corporate name of the PIP applicant:**

argenx BV

### Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, argenx BV submitted to the European Medicines Agency on 12 August 2022 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 17 October 2022.



## Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population and Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee members of Liechtenstein and Norway agree with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

## **Annex I**

### **Grounds for the granting of the waiver**

# 1. Waiver

## **1.1. Condition:**

Treatment of bullous pemphigoid

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product is likely to be unsafe  
and
- the paediatric population from 2 years to less than 18 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

## **Annex II**

### **Information about the authorised medicinal product**

***Information provided by the applicant:***

**Condition(s) and authorised indication(s)**

1. Treatment of generalised Myasthenia Gravis (gMG)

Authorised indication(s):

- Vyvgart is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
  - Invented name(s): Vyvgart
  - Authorised pharmaceutical form(s): Concentrate for solution for infusion
  - Authorised route(s) of administration: Intravenous use
  - Authorised via centralised procedure